Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Photoreceptors and Visual Pathways01:22

Photoreceptors and Visual Pathways

5.6K
At the molecular level, visual signals trigger transformations in photopigment molecules, resulting in changes in the photoreceptor cell's membrane potential. The photon's energy level is denoted by its wavelength, with each specific wavelength of visible light associated with a distinct color. The spectral range of visible light, classified as electromagnetic radiation, spans from 380 to 720 nm. Electromagnetic radiation wavelengths exceeding 720 nm fall under the infrared category,...
5.6K
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

433
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
433
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

389
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
389
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

4.0K
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.0K
Glaucoma: Overview01:25

Glaucoma: Overview

497
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
497
Non-LTR Retrotransposons03:18

Non-LTR Retrotransposons

11.4K
As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...
11.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Real-World Outcomes and Progression Patterns with First-Line Osimertinib in Patients with Advanced <i>EGFR</i>-Mutant Non-Small Cell Lung Cancer: A Nationwide Turkish Oncology Group Study.

Cancers·2026
Same author

A New Many-Objective Optimization Approach to Association Rule Mining: The NSGA-II/DE-ARM Algorithm.

Biomimetics (Basel, Switzerland)·2026
Same author

Comparative Efficacy of Stereotactic Body RadioTherapy (SBRT) and Percutaneous Radiofrequency Ablation (RFA) for Oligometastatic Liver Disease - Radiation Oncologists' Perspective and Practice Guideline.

The British journal of radiology·2026
Same author

Neoadjuvant nivolumab plus chemotherapy in resectable NSCLC: A pharmacological outcome study.

Pakistan journal of pharmaceutical sciences·2026
Same author

Global Disparities and Trends in Radiotherapy for Early-Stage Glottic Cancer.

Current oncology (Toronto, Ont.)·2026
Same author

Refractory Neuropathic Pain With Escalating Opioid Requirements and Ketamine Use in Advanced Degenerative Spine Disease: A Hospice Case Report.

The American journal of hospice & palliative care·2026

Related Experiment Video

Updated: May 31, 2025

Author Spotlight: Unraveling the Pathogenesis of Age-Related Macular Degeneration and Discovering Potential Therapies
06:16

Author Spotlight: Unraveling the Pathogenesis of Age-Related Macular Degeneration and Discovering Potential Therapies

Published on: July 28, 2023

2.4K

Lorlatinib-Induced Blindness: A Rare Entity.

Neris Dincer1, Orcun Can2, Gokhan Demir2

  • 1Department of Radiation Oncology, Acibadem Mehmet Ali Aydinlar University School of Medicine, Istanbul, Turkey.

Practical Radiation Oncology
|January 24, 2025
PubMed
Summary

Lorlatinib, a lung cancer drug, can cause rare optic nerve issues. This case highlights bilateral optic neuropathy, initially misdiagnosed, emphasizing the need for awareness of this potential side effect.

Area of Science:

  • Oncology
  • Ophthalmology
  • Pharmacology

Background:

  • Lorlatinib is a third-generation tyrosine kinase inhibitor for ALK-rearranged metastatic non-small cell lung cancer.

More Related Videos

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents
10:10

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents

Published on: February 15, 2022

1.3K
Laser-Induced Chronic Ocular Hypertension Model on SD Rats
06:34

Laser-Induced Chronic Ocular Hypertension Model on SD Rats

Published on: December 4, 2007

11.3K

Related Experiment Videos

Last Updated: May 31, 2025

Author Spotlight: Unraveling the Pathogenesis of Age-Related Macular Degeneration and Discovering Potential Therapies
06:16

Author Spotlight: Unraveling the Pathogenesis of Age-Related Macular Degeneration and Discovering Potential Therapies

Published on: July 28, 2023

2.4K
Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents
10:10

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents

Published on: February 15, 2022

1.3K
Laser-Induced Chronic Ocular Hypertension Model on SD Rats
06:34

Laser-Induced Chronic Ocular Hypertension Model on SD Rats

Published on: December 4, 2007

11.3K
  • Common side effects include hyperlipidemia, edema, neuropathy, and CNS effects.
  • Ocular side effects are rare with lorlatinib, unlike other ALK inhibitors.